1388150-85-3

Upstream product

• 1388150-83-1 1,6-anhydro-2-O-butyl-3-O-methyl-β-D-glucopyranose 
• 1388150-81-9 1,6-anhydro-2-O-butyl-4-O-(2-tetrahydropyranyl)-β-D-glucopyranose 
• 67313-50-2 1,6:2,3-dianhydro-4-O-(tetrahydropyran-2-yl)-β-D-mannopyranose 

Downstream Products

• 1388150-86-4 (methyl 2-O-benzoyl-3-O-methyl-α-L-idopyranosyluronate)-(1->4)-1,6-anhydro-2-O-butyl-3-O-methyl-β-D-glucopyranose 
• 1388150-87-5 (methyl 2-O-benzoyl-4-O-levulinoyl-3-O-methyl-α-L-idopyranosyluronate)-(1->4)-1,6-anhydro-2-O-butyl-3-O-methyl-β-D-glucopyranose 
• 1388150-88-6 (methyl 2-O-benzoyl-4-O-levulinoyl-3-O-methyl-α-L-idopyranosyluronate)-(1->4)-1,6-di-O-acetyl-2-O-butyl-3-O-methyl-α/β-D-glucopyranose 
• 1388150-90-0 (methyl 2-O-benzoyl-4-O-levulinoyl-3-O-methyl-α-L-idopyranosyluronate)-(1->4)-6-O-acetyl-2-O-butyl-3-O-methyl-α/β-D-glucopyranose trichloroacetimidate 
• 1388151-16-3 5-phenylpentyl (methyl 2-O-benzoyl-4-O-levulinoyl-3-O-methyl-α-L-idopyranosyluronate)-(1->4)-2-O-butyl-3-O-methyl-β-D-glucopyranoside 
• 1388150-92-2 5-phenylpentyl (methyl 2-O-benzoyl-4-O-levulinoyl-3-O-methyl-α-L-idopyranosyluronate)-(1->4)-2-O-butyl-3-O-methyl-α-D-glucopyranoside 
• 1388150-93-3 5-phenylpentyl (methyl 2-O-benzoyl-4-O-levulinoyl-3-O-methyl-α-L-idopyranosyluronate)-(1->4)-2-O-butyl-3-O-methyl-6-O-tert-butyldiphenylsilyl-β-D-glucopyranoside 
• 1388150-94-4 5-phenylpentyl (methyl 2-O-benzoyl-3-O-methyl-α-L-idopyranosyluronate)-(1->4)-2-O-butyl-3-O-methyl-6-O-tert-butyldiphenylsilyl-β-D-glucopyranoside 
• 1388150-95-5 (methyl 2-O-benzoyl-4-O-levulinoyl-3-O-methyl-α-L-idopyranosyluronate)-(1->4)-1-acetyl-2-O-butyl-3-O-methyl-α-D-glucopyranose 
• 1388150-96-6 (methyl 2-O-benzoyl-4-O-levulinoyl-3-O-methyl-α-L-idopyranosyluronate)-(1->4)-1-O-acetyl-2-O-butyl-3-O-methyl-6-O-tert-butyldiphenylsilyl-α-D-glucopyranose 

Relevant academic research and scientific papers

FGF RECEPTOR-ACTIVATING 3-O-ALKYL OLIGOSACCHARIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

The invention relates to the FGF receptor-activating oligosaccharides corresponding to formula (I) in which R1 represents an optionally substituted -O-alkyl group, R2 represents a hydroxyl group or an -O-alkyl group, R3, R5, R6, R7 and R8 represent -OSO3- or hydroxyl groups, R4 represents an NH-CO-alkyl or -O-alkyl group, R represents an -O-alkyl group, and n and m, which may be identical to or different from one another, represent integers equal to 0 or 1. Method for the preparation thereof and therapeutic use thereof.